Venus Concept gains as non-surgical robotic technology gets FDA clearance

Venus Concept

21/12/2022 13:56

** Shares of medical technology company Venus Concept Inc
 VERO.O  gain ~90% to $0.48 premarket
    ** Company receives U.S. FDA regulatory clearance for its
non-surgical robotic technology platform, AI.ME
    ** The platform offers physicians minimally-invasive
treatments for procedures requiring fractional skin resurfacing,
which reduces the appearance of scars 
    ** Company to introduce the first systems in 2023
    ** Up to Tuesday's close, stock down ~85% YTD
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com))